{"id":"NCT01063036","sponsor":"Bristol-Myers Squibb","briefTitle":"Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment","officialTitle":"A Study of the Safety and Efficacy of Entecavir Plus Tenofovir in Adults With Chronic Hepatitis B Virus Infection With Previous Nucleoside/Nucleotide Treatment Failure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2012-11","completion":"2014-02","firstPosted":"2010-02-05","resultsPosted":"2014-02-13","lastUpdate":"2014-12-15"},"enrollment":144,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis B"],"interventions":[{"type":"DRUG","name":"Entecavir","otherNames":["Baraclude®","BMS-200475"]},{"type":"DRUG","name":"Tenofovir","otherNames":["Viread®"]}],"arms":[{"label":"Entecavir + Tenofovir","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to show that the combination of entecavir and tenofovir, is effective and well tolerated in chronic hepatitis B patients who have failed previous treatment.","primaryOutcome":{"measure":"Percentage of Participants With a Virologic Response at Week 48 - Treated Population","timeFrame":"Week 48","effectByArm":[{"arm":"Entecavir + Tenofovir","deltaMin":76.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":28,"countries":["France","Germany","Italy","Netherlands","Poland","Romania","Spain"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":92},"commonTop":["Nasopharyngitis","Fatigue","Nausea","Arthralgia","Dyspepsia"]}}